Literature DB >> 7562997

Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease.

I Idänpään-Heikkilä1, E A Høiby, P Chattopadhyay, U Airaksinen, T M Michaelsen, E Wedege.   

Abstract

Antibodies to the meningococcal serosubtype-specific P1.7,16 protein and its variable regions (VR) were analysed in 28 convalescent sera drawn 8-36 months after systemic meningococcal disease by immunoblotting and enzyme immunoassay (EIA) methods. EIA antigens were the meningococcal P1.7,16 protein, produced in Bacillus subtilis, and peptides covering its VR1 (P1.7 region) and VR2 (P1.16 region) inserted into a bacterial penicillinase protein. In the immunoblotting method, three meningococcal reference strains were used; they expressed either the P1.7,16 protein, or only its VR1 or VR2 epitopes in their class 1 proteins. Both methods showed a strong IgG response in four sera to P1.7,16 and VR2, but not to VR1; 18 sera had no or weak anti-class 1 protein activity. The six remaining sera were positive only on blots. The VR2-specific sera had 30-fold higher bactericidal activity than those with negligible P1.7,16 responses. Previous vaccination of the patients with a B:15:P1.7,16 meningococcal vaccine was associated with a strong anti-P1.7,16 and anti-VR2 booster response that declined with time. The subtype-specific antibody activity in some sera indicated colonisation after disease by meningococci with class 1 proteins different from the strain that had caused disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562997     DOI: 10.1099/00222615-43-5-335

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  9 in total

1.  Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Authors:  E Wedege; K Bolstad; A Aase; T K Herstad; L McCallum; E Rosenqvist; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

Review 2.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

4.  Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.

Authors:  L G Milagres; M C Gorla; C T Sacchi; M M Rodrigues
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

5.  The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.

Authors:  D R Martin; N Ruijne; L McCallum; J O'Hallahan; P Oster
Journal:  Clin Vaccine Immunol       Date:  2006-04

6.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

7.  Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.

Authors:  Elisabeth Wedege; Betsy Kuipers; Karin Bolstad; Harry van Dijken; L Oddvar Frøholm; Clementien Vermont; Dominique A Caugant; Germie van den Dobbelsteen
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

8.  Humoral immune responses to Neisseria meningitidis in children.

Authors:  A J Pollard; R Galassini; E M van der Voort; R Booy; P Langford; S Nadel; C Ison; J S Kroll; J Poolman; M Levin
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

9.  Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.

Authors:  Ojas H Mehta; Gunnstein Norheim; J Claire Hoe; Christine S Rollier; Jerry C Nagaputra; Katherine Makepeace; Muhammad Saleem; Hannah Chan; David J P Ferguson; Claire Jones; Manish Sadarangani; Derek W Hood; Ian Feavers; Jeremy P Derrick; Andrew J Pollard; E Richard Moxon
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.